Treatment for Outpatients with Comorbid Schizophrenia and Substance Use Disorders: A Review

被引:30
|
作者
De Witte, Nele A. J. [1 ]
Crunelle, Cleo L. [1 ]
Sabbe, Bernard [1 ,2 ]
Moggi, Franz [4 ,5 ]
Dom, Geert [1 ,3 ]
机构
[1] Univ Antwerp, Collaborat Antwerp Psychiat Res Inst, BE-2610 Antwerp, Belgium
[2] Psychiat Hosp St Norbertushuis, Duffel, Belgium
[3] Psychiat Ctr Alexian Bros, Boechout, Belgium
[4] Univ Hosp Psychiat Bern, Bern, Switzerland
[5] Univ Fribourg, Dept Psychol, CH-1700 Fribourg, Switzerland
关键词
Dual disorder; Schizophrenia; Substance use disorder; Randomized controlled trial; Efficacy; SEVERE MENTAL-ILLNESS; ASSERTIVE COMMUNITY TREATMENT; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; FAMILY INTERVENTION; DUAL DIAGNOSIS; MOTIVATIONAL INTERVENTION; DRUG-ABUSE; OUTCOMES; PEOPLE;
D O I
10.1159/000355267
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Aims: This review provides evidence of which interventions need to be part of effective outpatient integrated treatment for patients with comorbid schizophrenia and substance use disorders. Methods: A total of 14 randomized controlled trials were included. Effect sizes are provided to assess the magnitude of the treatments' efficacy. Results: Despite the studies' heterogeneity, we can conclude that certain programs (e. g. Behavioral Treatment for Substance Abuse in Severe and Persistent Mental Illness) and specific interventions (e. g. motivational interviewing, family interventions) seem to be effective. Moreover, programs integrating multiple interventions are more likely to be positively related to better outcomes than single interventions. Finally, the lack of difference between effect sizes of assertive community treatment compared to case management suggests that a lower caseload is not necessary for positive treatment outcomes. Conclusion: Integrated treatment seems advantageous, although effect sizes are mostly modest. More homogeneous and qualitative sound studies are needed. (C) 2013 S. Karger AG, Basel
引用
收藏
页码:105 / 114
页数:10
相关论文
共 50 条
  • [1] Treatment of patients with schizophrenia and comorbid substance use disorders
    Dilbaz, Nesrin
    Darcin, Asli Enez
    [J]. KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 21 (01): : 80 - 90
  • [2] Treating comorbid substance use disorders in schizophrenia
    Lubman, Dan I.
    King, Joel A.
    Castle, David J.
    [J]. INTERNATIONAL REVIEW OF PSYCHIATRY, 2010, 22 (02) : 191 - 201
  • [3] Premorbid functioning in schizophrenia spectrum disorders with comorbid substance use: A systematic review
    Prat, Gemma
    Marquez-Arrico, Julia E.
    Rio-Martinez, Laura
    Navarro, Jose Francisco
    Adan, Ana
    [J]. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2021, 110
  • [4] Morbidity and mortality in schizophrenia with comorbid substance use disorders
    Lahteenvuo, Markku
    Batalla, Albert
    Luykx, Jurjen J.
    Mittendorfer-Rutz, Ellenor
    Tanskanen, Antti
    Tiihonen, Jari
    Taipale, Heidi
    [J]. ACTA PSYCHIATRICA SCANDINAVICA, 2021, 144 (01) : 42 - 49
  • [5] Treatment of schizophrenia in subjects with substance use disorders:: A review
    Valladolid, GR
    Brugué, MC
    [J]. ACTAS ESPANOLAS DE PSIQUIATRIA, 2001, 29 (02): : 124 - 130
  • [6] Treatment of Schizophrenia and Comorbid Substance Use Disorder
    Green, Alan, I
    Salomon, Melinda S.
    Brenner, Mark J.
    Rawlins, Kimberly
    [J]. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2002, 1 (02) : 129 - 139
  • [7] Integrated treatment for comorbid eating disorders and substance use disorders: a scoping review protocol
    Miller, Molly
    Bartel, Sara
    Hunter, Abbey
    Boulos, Leah
    Lacroix, Emilie
    [J]. JBI EVIDENCE SYNTHESIS, 2023, 21 (12) : 2465 - 2473
  • [8] Comorbid substance use disorders in schizophrenia: A latent class approach
    Kerner, Befit
    [J]. PSYCHIATRY RESEARCH, 2015, 225 (03) : 395 - 401
  • [9] The prevalence of comorbid anxiety disorders in outpatients with schizophrenia
    Nebioglu, Melike
    Altindag, Abdurrahman
    [J]. INTERNATIONAL JOURNAL OF PSYCHIATRY IN CLINICAL PRACTICE, 2009, 13 (04) : 312 - 317
  • [10] Pharmacological treatment of schizophrenia with comorbid substance use disorder
    Azorin, Jean-Michel
    Simon, Nicolas
    Adida, Marc
    Belzeaux, Raoul
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (02) : 231 - 253